The ID3 Knockout AGS Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human gastric adenocarcinoma AGS cell line, featuring targeted disruption of the ID3 gene. This polyclonal pool offers a heterogeneous loss-of-function model for studying the biological functions of ID3 without clonal selection artifacts. The use of CRISPR/Cas9-mediated gene disruption ensures efficient editing while maintaining the genetic diversity inherent in a polyclonal population, making it suitable for functional genomics screening and pooled phenotypic assays.
The parental AGS cell line is a well-characterized model of human gastric adenocarcinoma, widely employed in cancer biology research to investigate tumor cell proliferation, invasion, and signaling mechanisms. Originating from a gastric tumor, AGS cells retain key features of gastric cancer, including responsiveness to growth factors and oncogenic signaling pathways. This host cell line provides a relevant background for examining the role of ID3 in gastric carcinogenesis and for evaluating potential therapeutic targets.
ID3 encodes a dominant-negative helix-loop-helix (HLH) protein that lacks a DNA-binding domain, thereby sequestering E-proteins such as TCF3, TCF4, and TCF12 and preventing their transcriptional activation of target genes, including the cell cycle inhibitors p21/CDKN1A and p16INK4a. By repressing these negative regulators, ID3 promotes cell cycle progression and inhibits differentiation. ID3 is activated downstream of multiple signaling pathways: TGF-?? signaling through SMAD2/3, BMP signaling via SMAD1/5/8, and Notch signaling through NICD. Additionally, transcription factors ETS1 and HIF-1?? regulate ID3 expression. ID3 interacts with RB1 and coactivators like p300/CBP, positioning it as a central node coordinating proliferation and differentiation signals.
In AGS gastric cancer cells, ID3 is frequently overexpressed, contributing to sustained proliferation and resistance to differentiation cues. Knockout of ID3 in this polyclonal population is expected to relieve inhibition of E-protein activity, leading to upregulation of p21 and p16, cell cycle arrest, and enhanced apoptosis. This model enables dissection of ID3??s role in maintaining the tumorigenic phenotype of gastric cancer cells, including its potential impact on epithelial-to-mesenchymal transition (EMT) and metastatic behavior. By disrupting ID3 in a gastric cancer context, researchers can explore the therapeutic vulnerability of ID3-dependent tumor maintenance.
The ID3 Knockout AGS Polyclonal Cells are suitable for a wide range of applications, including RT-qPCR and western blotting to confirm knockout and assess downstream effectors (e.g., p21, cyclin D1), cell proliferation assays (MTT, BrdU), cell cycle analysis by flow cytometry, apoptosis assays (Annexin V), colony formation assays, and migration/invasion studies. Transcriptomic profiling via RNA-seq can reveal global gene expression changes, while ChIP-qPCR and reporter assays enable investigation of E-box occupancy and E-protein activity. These cells are ideal for functional genomics screens, drug target validation, and mechanistic studies of ID3-mediated signaling in gastric cancer. For further information, please contact Ascent Research.
